David P. Dearnaley, MD, on Helping Patients Tolerate Radiation Therapies for Prostate Cancer

Posted: Wednesday, February 19, 2020

David P. Dearnaley, MD, of The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, discusses his observations on toxicities associated with hypofractionated high-dose intensity modulated radiotherapy, and ways to help mitigate side effects.